Biopharm Services

News from BPS


Feb 2012: New Technology Grant

1 FEB 2011: Biopharm Services has been awarded a UK Technology Strategy Board grant to develop our software bioprocess database application to support rapid bioprocess development and technology transfer to manufacturing. Extending the functionality of the BioSolve platform to recipe management and facility fit.


New Newsletter published

New Newsletter published October 2011. Gives details of the exciting changes happening with the BioSolve Suite.


Annual Bioprocess Simulation prize

Biopharm Service's Annual Bioprocess Simulation prize was awarded in November 2011 to a team of undergraduate students at UCL's Department of Biochemical Engineering for their work on "Application of BioSolve computer simulation tool for investigating the process economics of antibody production". The BioSolve modelling tool was used to evaluate the economics of a process to produce an IgG antibody for treating arthritis and to understand impact of scale-up to and for process optimisation. This demonstrates the value of BioSolve to help students within the teaching programmes at UCL to understand the impact of process and technology choices.
Download the UCL BioSolve poster


Past President of the IChemE joins the Biopharm Team

Bioprocess specialist Stephen Vranch joins Biopharm Services. Since 1968 Stephen has held senior positions in Project and Process Engineering, Fermentation and Process Development and in Production of Diagnostics and Biological Therapeutic Pharmaceuticals, including licensed bulk product. Stephen was a former President of the IChemE. As our lead consultant, Stephen specialises on all aspects of CGMP regulatory compliance.


BioSolve

BioSolve used to generate data for GE lifecycle assessment of the entire monocloncal antibody production process: a comparison of multi-use and single-use processes. Upcoming webinar

Adoption of BioSolve Process in UCL Biochemical Engineering Courses

BioPharm Services is pleased to announce the adoption of BioSolve Process by the Biochemical Engineering Department of University College London (UCL). The cost modelling software has been used for both undergraduate and postgraduate courses including the MBI® programme (Modular Training for the Bioprocess Industries). MORE »



CLIENT FEEDBACK

Click on logo for feedback



Biopharm Software Services

Promedior Inc Feedback

'BioSolve is an excellent tool for planning early stage process development alternatives.'

'BioSolve provides a quantitative edge when presenting proposed directions to investors.'

'BioSolve enables us to focus on potential process bottlenecks in terms of cost or throughput.'

Scott Willett, Director biopharmaceutical development, Promedior Inc

Dow Pharmaceuticals Feedback

'One hidden benefit of BioSolve is that it is comes populated with an enormous wealth of historical industry data and this allows us to benchmark Pfēnex Expression Technology's performance more accurately than we would be able to do with internal data alone.

'This enables us to better articulate the key Cost of Goods advantages realized by our clients'

Patrick Lucy, Global Business Development Leader, Pfēnex Inc, Dow Pharmaceuticals

Xcellerex Inc Feedback

'BioSolve has been a very useful tool for demonstrating to our prospective customers the benefit of disposables and the FlexFactory platform.'

'One hidden benefit of BioSolve is that it is comes populated with an enormous wealth of historical industry data and this allows us to benchmark more accurately than we would be able to do with internal data alone.'

'We use BioSolve with prospective customers to plug their specific numbers into the model. All the data and assumptions are clearly presented for review and discussion. The Excel format and preset templates allows BioSolve to be reconfigured quickly and easily at a high level or manipulated at a very detailed level, depending upon the needs and sophistication of the user.'

Geoff Hodge, Managing Director - Technology, Xcellerex Inc.

Sanofi Pasteur Feedback

'Validating investment scenarios is a key part of developing our business strategy and is used to set priorities. With BioSolve, what used to take months now can be evaluated in a day! We were amazed recently when on a particular case we were able to generate comparable and coherent results in a day that did take us months manually to prepare. Not only does this save a lot of time it helps us to carry out sensitivity and 'what if' scenario analyses with BioSolve, this supports better informed decision making.'

Jean-Marc Guillaume, Head of cell culture and virology, Sanofi Pasteur vaccines

Avecia Biologics Feedback

'BPS models provide Insight into the complexities of biotech plants, It helps to set Direction in projects and improvement programmes'

Bruce Williams Avecia Biologics

Millipore Feedback

'It is important for the customer to select the right mix of Mobius® single-use solutions to optimize their manufacturing process and maximize the return on investment. BioSolve, an industry wide popular modeling package allows the customers to map their process and develop cost of ownership models'.

Vikas Gupta, Group Product Manager, Advanced Manufacturing Solutions, Millipore corporation

BioSolve Industry User forum



The BioSolve User forum is intended to exchange and learn from industry peers working with BioSolve. For more information and to organise a live webex demonstration of this tool please contact us.

Biopharm Services have been developing Process modelling tools since 1998 with over 100 process models successfully implemented to date. BioSolve was launched in Q4 2008 as the first standalone cost modelling tool designed explicitly to compare process technologies and expression systems. BioSolve is the fruit of many years of fine tuning, bringing to the market an invaluable off-the-shelf tool that can be rapidly adapted to specific companies needs.

Authorised references of companies who have adopted BioSolve since launch and many more confidential clients;

End-Users: Pfizer, Sanofi Aventis Group, Sanofi Pasteur Vaccines, Medimmune Corporation, MSD Biologics/Avecia, DSM Biologics, Ipsen, Pierre Fabre

Suppliers: Millipore Corporation, Xcellerex, Artelis, Pfenex, Pall Corporation